Literature DB >> 21435612

Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach.

Francesco Burzotta1, Carlo Trani, Daniel Todaro, Luca Mariani, Giovanni Paolo Talarico, Antonella Tommasino, Maura Giammarinaro, Giampaolo Niccoli, Italo Porto, Antonio Maria Leone, Rocco Mongiardo, Mario Attilio Mazzari, Giovanni Schiavoni, Filippo Crea.   

Abstract

OBJECTIVES: This study sought to compare the procedural performance and the acute angiographic result on side-branch ostium obtained using 2 different drug-eluting stents (DES) to treat patients with bifurcated coronary lesions.
BACKGROUND: Drug-eluting stents are routinely used in percutaneous coronary interventions (PCI) of bifurcated coronary lesions. Different DES types have major technical differences that may influence the procedural and clinical performance in bifurcation PCI.
METHODS: Consecutive patients with bifurcated lesions undergoing DES implantation using a systematic provisional-stenting strategy were randomized to sirolimus-eluting stent (SES) or everolimus-eluting stent (EES) before intervention. The procedural details for PCI were prospectively recorded to assess the occurrence of any trouble in the side-branch (SB) management (primary end point). Post-PCI angiographic result (primary end point: minimal lumen diameter at SB ostium) was evaluated offline by 3-dimensional reconstruction and quantitative coronary analysis. Clinical outcome was prospectively recorded up to 18 months to assess the occurrence of target bifurcation failure.
RESULTS: A total of 150 patients were enrolled in the study (29% diabetics, 17% unprotected left main). The stent was successfully implanted according to randomization in all cases. Procedural performance was not significantly different between the 2 kinds of DES. Three-dimensional reconstruction and quantitative coronary analysis showed similar post-PCI results in the main vessel and better results in the SB with EES than with SES (minimal lumen diameter at SB ostium: 1.94 ± 0.72 mm vs. 1.64 ± 0.62 mm; p = 0.013). At 18 months, target bifurcation failure occurred in 7 (9.0%) of SES-treated patients versus 8 (10.7%) of EES patients (p = 0.57).
CONCLUSIONS: In patients with bifurcated lesions treated by provisional stenting technique, EES compared with SES is associated with similar procedural performance and better 3-dimensional reconstruction and quantitative coronary analysis result in the SB. Both DES are associated with low rates of major adverse events and angiographic failure. (Sirolimus Versus Everolimus-Eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical Significance of Residual Side-Branch Stenosis [SEA-SIDE]; NCT00697372).
Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21435612     DOI: 10.1016/j.jcin.2010.12.005

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  10 in total

1.  Clinical outcome after percutaneous treatment of de novo coronary bifurcation lesions using first or second generation of drug-eluting stents.

Authors:  Miroslaw Ferenc; Heinz Joachim Buettner; Michael Gick; Thomas Comberg; Juergen Rothe; Firas Khoury; Christian Valina; Aurel Toma; Piotr Kuebler; Florian Riede; Franz-Josef Neumann
Journal:  Clin Res Cardiol       Date:  2015-09-02       Impact factor: 5.460

2.  Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials.

Authors:  Antoinette de Waha; Salvatore Cassese; Duk-Woo Park; Francesco Burzotta; Robert A Byrne; Tomohisa Tada; Lamin A King; Seung-Jung Park; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2012-03-16       Impact factor: 5.460

3.  Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial.

Authors:  Masahiro Yamawaki; Toshiya Muramatsu; Kazuhiro Ashida; Koichi Kishi; Yoshihiro Morino; Yoshihisa Kinoshita; Takashi Fujii; Yuichi Noguchi; Shingo Hosogi; Kazuya Kawai; Kiyoshi Hibi; Yoshisato Shibata; Hiroshi Ohira; Yasuhiro Morita; Yasuhiro Tarutani; Mikihito Toda; Yoshihisa Shimada; Yuji Ikari; Jiro Ando; Yutaka Hikichi; Yoritaka Otsuka; Yasushi Fuku; Shigenori Ito; Harumi Katoh; Kazushige Kadota; Yoshiaki Ito; Kazuaki Mitsudo
Journal:  Heart Vessels       Date:  2019-03-11       Impact factor: 2.037

Review 4.  Stenting of coronary bifurcation lesions: a literature and technical review.

Authors:  Joo Myung Lee; Kyung Woo Park; Bon-Kwon Koo; Hyo-Soo Kim
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

5.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients.

Authors:  Eliano Pio Navarese; Mariusz Kowalewski; David Kandzari; Alexandra Lansky; Bartosz Górny; Lukasz Kołtowski; Ron Waksman; Sergio Berti; Giuseppe Musumeci; Ugo Limbruno; Rene J van der Schaaf; Malte Kelm; Jacek Kubica; Harry Suryapranata
Journal:  Open Heart       Date:  2014-08-21

6.  Five-year clinical outcomes of first-generation versus second-generation drug-eluting stents following coronary chronic total occlusion intervention.

Authors:  Yong Hoon Kim; Ae-Young Her; Seung-Woon Rha; Byoung Geol Choi; Se Yeon Choi; Jae Kyeong Byun; Yoonjee Park; Dong Oh Kang; Won Young Jang; Woohyeun Kim; Ju Yeol Baek; Woong Gil Choi; Tae Soo Kang; Jihun Ahn; Sang-Ho Park; Ji Young Park; Min-Ho Lee; Cheol Ung Choi; Chang Gyu Park; Hong Seog Seo
Journal:  J Geriatr Cardiol       Date:  2019-08       Impact factor: 3.327

Review 7.  Everolimus-eluting stents in interventional cardiology.

Authors:  Jacob C Townsend; Phillip Rideout; Daniel H Steinberg
Journal:  Vasc Health Risk Manag       Date:  2012-06-27

8.  Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis.

Authors:  Eliano P Navarese; Kenneth Tandjung; Bimmer Claessen; Felicita Andreotti; Mariusz Kowalewski; David E Kandzari; Dean J Kereiakes; Ron Waksman; Laura Mauri; Ian T Meredith; Aloke V Finn; Hyo-Soo Kim; Jacek Kubica; Harry Suryapranata; Toni Mustahsani Aprami; Giuseppe Di Pasquale; Clemens von Birgelen; Elvin Kedhi
Journal:  BMJ       Date:  2013-11-06

9.  First-Generation Versus Second-Generation Drug-Eluting Stents in Coronary Chronic Total Occlusions: Two-Year Results of a Multicenter Registry.

Authors:  Jong-Hwa Ahn; Jeong Hoon Yang; Cheol Woong Yu; Je Sang Kim; Hyun Jong Lee; Rak Kyeong Choi; Tae Hoon Kim; Ho Joon Jang; Young Jin Choi; Young Moo Roh; Won-Heum Shim; Young Bin Song; Joo-Yong Hahn; Jin-Ho Choi; Sang Hoon Lee; Hyeon-Cheol Gwon; Seung-Hyuk Choi
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

10.  Long-term outcome and chest pain in patients with true versus non-true bifurcation lesions treated with second-generation drug-eluting stents in the TWENTE trial.

Authors:  K Gert van Houwelingen; Liefke C van der Heijden; Ming Kai Lam; Marlies M Kok; Marije M Löwik; J W Louwerenburg; Gerard C M Linssen; Maarten J IJzerman; Carine J M Doggen; Clemens von Birgelen
Journal:  Heart Vessels       Date:  2016-01-08       Impact factor: 2.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.